The bio/pharma companies used to build and staff dedicated manufacturing capacities for drugs in development only to see them cancelled if the product failed in Phase III of clinical research; working with a CDMO limits that financial risk. Using a CDMO also allows to get advantage of specific expertise and capability. Some CDMO are specialized in manufacturing of injectable (CDM Lavoisier, etc...), vaccines, cytotoxics, ... When a company doesn't have that capability in house, CDMO offer a quick turnkey solution.
